Table 2 Characteristics of side effects
EVG/c/FTC/TAF | DOR/3TC/TDF | p-value | |
|---|---|---|---|
n = 128 | n = 94 | ||
Occurrence of at least one side effect, n (%) | 38 (29.7%) | 36 (38%) | 0.11 |
Discontinuation of treatment due to poor tolerance | 5 (3.9%) | 1 (1.1%) | 0.40 |
Clinical side effects | |||
Digestive side effect: nausea or vomiting n (%) | 14 (10.1%) | 13 (13.8%) | |
Digestive side effect: diarrhea, n (%) | 8 (6.2%) | 8 (8.5%) | |
Rash | 2 (1.6%) | 1 (1.1%) | |
Mucous membrane lesions | 0 | 1 (1.1%) | |
Headache | 2 (1.6%) | 1 (1.1%) | |
Fatigue, discomfort | 2 (1.6%) | 5 (5.3%) | |
Myalgia | 0 | 1 (1.1%) | |
Sleep disorders, anxiety | 0 | 1 (1.1%) | |
Dysgueusia | 0 | 1 (1.1%) | |
Hypersalivation | 0 | 1 (1.1%) | |
Increase in AST and ALT | 3 (2.3%) | 0 | |
Not specified | 6 (4.7%) | 9 (9.6%) | |
Impact on daily life, n | n = 125 | n = 89 | |
No discomfort, n (%) | 103 (82.4%) | 67 (75.3%) | |
Moderate discomfort, n (%) | 16 (12.8%) | 19 (21.3%) | |
Significant discomfort, n (%) | 5 (4%) | 3 (3.4%) | |
Major discomfort, n (%) | 1 (0.8%) | 0 | |